Work

Design of a phase II trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in EGFR inhibitor-resistant, c-Met+ NSCLC

Year: 2016

Type: article

Study design: Study Protocol

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw383.87

Authors: Y.-L. Wu, K. Park, D.-W. Kim, R. Soo, U. Stammberger, W. Chen, G. Locatelli, J. Yang

Institutions: Guangdong General Hospital, Samsung Medical Center, Sungkyunkwan University, Seoul National University Hospital, National University Cancer Institute, Singapore, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587545056

FWCI:

Cites:

Cited by:

Related to: 10